735 related articles for article (PubMed ID: 33938697)
1. Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic.
Kearns DG; Uppal S; Chat VS; Wu JJ
J Drugs Dermatol; 2021 May; 20(5):582-583. PubMed ID: 33938697
[No Abstract] [Full Text] [Related]
2. Chronic tearing induced by apremilast.
Norris MR; Bielory L
Ann Allergy Asthma Immunol; 2018 Sep; 121(3):375. PubMed ID: 29969663
[No Abstract] [Full Text] [Related]
3. Apremilast in the treatment of psoriasis and psoriatic arthritis.
Gooderham M; Papp K
Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
[TBL] [Abstract][Full Text] [Related]
4. Apremilast for the management of moderate to severe plaque psoriasis.
Vangipuram R; Alikhan A
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
[TBL] [Abstract][Full Text] [Related]
5. Real-world use of apremilast for patients with psoriasis in Japan.
Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
[TBL] [Abstract][Full Text] [Related]
6. Drug safety evaluation of apremilast for treating psoriatic arthritis.
Busa S; Kavanaugh A
Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
[TBL] [Abstract][Full Text] [Related]
7. Safety evaluation of apremilast for the treatment of psoriasis.
Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
9. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
Sobell JM; Foley P; Toth D; Mrowietz U; Girolomoni G; Goncalves J; Day RM; Chen R; Yosipovitch G
Acta Derm Venereol; 2016 May; 96(4):514-20. PubMed ID: 26837052
[TBL] [Abstract][Full Text] [Related]
10. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
Palfreeman AC; McNamee KE; McCann FE
Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
Paller AS; Hong Y; Becker EM; de Lucas R; Paris M; Zhang W; Zhang Z; Barcellona C; Maes P; Fiorillo L
J Am Acad Dermatol; 2020 Feb; 82(2):389-397. PubMed ID: 31408686
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG
J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
[TBL] [Abstract][Full Text] [Related]
14. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
Moustafa F; Feldman SR
Dermatol Online J; 2014 May; 20(5):22608. PubMed ID: 24852768
[TBL] [Abstract][Full Text] [Related]
15. Synergistic cytokine effects as apremilast response predictors in patients with psoriasis.
Garcet S; Nograles K; Correa da Rosa J; Schafer PH; Krueger JG
J Allergy Clin Immunol; 2018 Sep; 142(3):1010-1013.e6. PubMed ID: 29936103
[No Abstract] [Full Text] [Related]
16. Is apremilast for psoriasis as effective and safe as reported in clinical trials? Five-year experience from a Greek tertiary hospital: long-term real-life efficacy and safety of apremilast in Greece.
Sotiriou E; Tsentemeidou A; Vakirlis E; Sideris N; Bakirtzi K; Papadimitriou I; Lallas A; Ioannides D
Clin Exp Dermatol; 2021 Dec; 46(8):1542-1544. PubMed ID: 33811368
[TBL] [Abstract][Full Text] [Related]
17. Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis.
Phan C; Beneton N; Delaunay J; Reguiai Z; Boulard C; Fougerousse AC; Cinotti E; Romanelli M; Mery-Bossard L; Thomas-Beaulieu D; Parier J; Maccari F; Chaby G; Bastien M; Begon E; Samimi M; Prignano F; Beauchet A; Mahé E;
Drugs Aging; 2020 Sep; 37(9):657-663. PubMed ID: 32696432
[TBL] [Abstract][Full Text] [Related]
18. Otezla, Warts and All, Racks Up Sales and Eyes Blockbuster Status.
Reinke T
Manag Care; 2017 Oct; 26(10):8-9. PubMed ID: 29068290
[TBL] [Abstract][Full Text] [Related]
19. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Deeks ED
Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
[TBL] [Abstract][Full Text] [Related]
20. An update on the safety of apremilast for the treatment of plaque psoriasis.
Shavit E; Shear NH
Expert Opin Drug Saf; 2020 Apr; 19(4):403-408. PubMed ID: 32182143
[No Abstract] [Full Text] [Related]
[Next] [New Search]
